Invesco
KALV

Invesco’s KalVista Pharmaceuticals KALV Stock Holding History

Invesco’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
75,282
-2,582
-3% -$41.6K ﹤0.01% 2675
2025
Q4 		$1.26M Buy
77,864
+14,621
+23% +$194K ﹤0.01% 2810
2025
Q3 		$770K Buy
63,243
+12,482
+25% +$172K ﹤0.01% 3045
2025
Q2 		$574K Buy
50,761
+10,957
+28% +$134K ﹤0.01% 3102
2025
Q1 		$459K Buy
39,804
+24,164
+155% +$247K ﹤0.01% 3184
2024
Q4 		$132K Buy
15,640
+1,083
+7% +$11.2K ﹤0.01% 3588
2024
Q3 		$169K Buy
14,557
+277
+2% +$3.48K ﹤0.01% 3549
2024
Q2 		$168K Buy
14,280
+308
+2% +$3.59K ﹤0.01% 3668
2024
Q1 		$166K Buy
13,972
+495
+4% +$6.6K ﹤0.01% 3682
2023
Q4 		$165K Buy
+13,477
New +$123K ﹤0.01% 3600
2023
Q2 		– Sell
-10,147
Closed -$79.8K – 3899
2023
Q1 		$79.8K Sell
10,147
-1,071
-10% -$7.99K ﹤0.01% 3721
2022
Q4 		$75.8K Buy
+11,218
New +$60.1K ﹤0.01% 3863
2021
Q4 		– Sell
-10,222
Closed -$178K – 4072
2021
Q3 		$178K Sell
10,222
-145,618
-93% -$2.95M ﹤0.01% 3839
2021
Q2 		$3.73M Buy
+155,840
New +$4.08M ﹤0.01% 2574
2020
Q2 		– Sell
-10,884
Closed -$83K – 3666
2020
Q1 		$83K Buy
+10,884
New +$147K ﹤0.01% 3583
2019
Q4 		– Sell
-11,257
Closed -$130K – 3672
2019
Q3 		$130K Sell
11,257
-247,416
-96% -$4M ﹤0.01% 3608
2019
Q2 		$5.73M Sell
258,673
-55,118
-18% -$1.29M ﹤0.01% 2097
2019
Q1 		$8.98M Buy
313,791
+37,268
+13% +$808K ﹤0.01% 1641
2018
Q4 		$5.46M Buy
+276,523
New +$5.56M ﹤0.01% 1886
2015
Q3 		– Sell
-54
Closed -$5K – 3888
2015
Q2 		$5K Buy
+54
New +$5.36K ﹤0.01% 4202

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco's KALV Position: Q1 2026 in Review

Invesco reduced its KalVista Pharmaceuticals (KALV) stake by 3.3% in Q1 2026, selling an estimated $41.6K and leaving 75,282 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.

Invesco first reported a position in KALV in Q2 2015 and has held it in 20 quarters since. The position peaked at $8.98M in Q1 2019. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Invesco held 75,282 shares of KalVista Pharmaceuticals worth $1.52M as of Q1 2026.
  • Invesco sold 2,582 KalVista Pharmaceuticals shares in Q1 2026, an estimated $41.6K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2675 holding.
  • Invesco first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 20 quarters since.
  • Invesco's KalVista Pharmaceuticals position peaked at $8.98M in Q1 2019.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.